• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用一种新型照片辅助工具评估患者自评的血管性水肿严重程度,以预测非肥大细胞介质诱导的血管性水肿诊断。

Patient-rated angioedema severity using a novel photo-aid for predicting non-mast cell mediator-induced angioedema diagnosis.

作者信息

Wongsa Chamard, Phinyo Phichayut, Dharakul Tararaj, Sompornrattanaphan Mongkhon, Srisuwatchari Witchaya, Thongngarm Torpong

机构信息

Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

出版信息

World Allergy Organ J. 2023 Jun 27;16(6):100784. doi: 10.1016/j.waojou.2023.100784. eCollection 2023 Jun.

DOI:10.1016/j.waojou.2023.100784
PMID:37435178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10331577/
Abstract

BACKGROUND

Patients with non-mast cell mediator-induced angioedema (NM-AE) usually experience a diagnostic delay. Therefore, a clinical tool for predicting NM-AE diagnosis is essential.

OBJECTIVE

To identify clinical predictors related to a confirmed diagnosis of NM-AE.

METHODS

Participants with a history of recurrent AE with unknown causes were enrolled. They were classified into mast cell mediator-induced AE (M-AE) and NM-AE according to the response to anti-mast cell mediator therapy. All participants were asked to rate their worst AE ever experienced (% Photomax) from 0 to 100% using a novel photo aid. Clinical characteristics were recorded and analyzed by univariable and multivariable analysis.

RESULTS

Thirty-five participants were included, 25 with NM-AE and 10 with M-AE. AE located at extremities, face, and genitalia and positive family history were significantly associated with NM-AE. The AE severity in the NM-AE group was significantly higher than in the M-AE group, with the mean % Photomax of 82.4 ± 20.3 vs 47.5 ± 25.6 (p < 0.001), respectively. Univariable analysis showed that the % Photomax (every 10% increase), feet AE and hands AE were predictive of being NM-AE with the area under the receiver operating characteristic curve (AuROC) of 0.87 (95% CI 0.75, 0.99), 0.85 (95% CI 0.72, 0.98), and 0.84 (0.69, 0.99), respectively. Multivariable analysis showed that the combination of hands AE and % Photomax enhanced diagnostic accuracy (AuROC 0.94, 95% CI 0.86, 1.0) and constituted the prototype formula for calculating the diagnostic probability.

CONCLUSION

Patient-rated angioedema severity using a novel photo aid combined with hands AE had a high probability of diagnosing NM-AE.

摘要

背景

非肥大细胞介质诱导性血管性水肿(NM-AE)患者通常会经历诊断延迟。因此,一种预测NM-AE诊断的临床工具至关重要。

目的

确定与确诊NM-AE相关的临床预测因素。

方法

纳入有不明原因复发性血管性水肿病史的参与者。根据对抗肥大细胞介质治疗的反应,将他们分为肥大细胞介质诱导性血管性水肿(M-AE)和NM-AE。所有参与者均被要求使用一种新颖的照片辅助工具,将他们经历过的最严重血管性水肿(% Photomax)从0到100%进行评分。记录临床特征,并通过单变量和多变量分析进行分析。

结果

共纳入35名参与者,其中25名患有NM-AE,10名患有M-AE。位于四肢、面部和生殖器的血管性水肿以及阳性家族史与NM-AE显著相关。NM-AE组的血管性水肿严重程度显著高于M-AE组,平均% Photomax分别为82.4±20.3和47.5±25.6(p<0.001)。单变量分析显示,% Photomax(每增加10%)、足部血管性水肿和手部血管性水肿可预测为NM-AE,受试者工作特征曲线下面积(AuROC)分别为0.87(95%CI 0.7,5 0.99)、0.85(95%CI 0.72,0.98)和0.84(0.69,0.99)。多变量分析显示,手部血管性水肿和% Photomax的组合提高了诊断准确性(AuROC 0.94,95%CI 0.86,1.0),并构成了计算诊断概率的原型公式。

结论

使用新颖照片辅助工具结合手部血管性水肿进行患者自评血管性水肿严重程度,对NM-AE的诊断具有较高概率。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6377/10331577/95bc3a27294e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6377/10331577/6977a06e81dc/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6377/10331577/95bc3a27294e/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6377/10331577/6977a06e81dc/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6377/10331577/95bc3a27294e/gr3.jpg

相似文献

1
Patient-rated angioedema severity using a novel photo-aid for predicting non-mast cell mediator-induced angioedema diagnosis.使用一种新型照片辅助工具评估患者自评的血管性水肿严重程度,以预测非肥大细胞介质诱导的血管性水肿诊断。
World Allergy Organ J. 2023 Jun 27;16(6):100784. doi: 10.1016/j.waojou.2023.100784. eCollection 2023 Jun.
2
Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell-Mediated Angioedema.缓激肽介导的血管性水肿与肥大细胞介导的血管性水肿在机制和临床表型方面的差异与相似之处。
Clin Rev Allergy Immunol. 2021 Aug;61(1):40-49. doi: 10.1007/s12016-021-08841-w. Epub 2021 Feb 3.
3
Clinical Features of Hereditary and Mast Cell-mediated Angioedema Focusing on the Differential Diagnosis in Japanese Patients.遗传性和肥大细胞介导的血管性水肿的临床特征:聚焦于日本患者的鉴别诊断
Intern Med. 2018 Feb 1;57(3):319-324. doi: 10.2169/internalmedicine.8624-16. Epub 2017 Nov 1.
4
Clinical similarities among bradykinin-mediated and mast cell-mediated subtypes of non-hereditary angioedema: a retrospective study.缓激肽介导型与肥大细胞介导型非遗传性血管性水肿的临床相似性:一项回顾性研究
Clin Transl Allergy. 2015 Feb 4;5(1):5. doi: 10.1186/s13601-015-0049-8. eCollection 2015.
5
Clinical and laboratory characteristics that differentiate hereditary angioedema in 72 patients with angioedema.72例血管性水肿患者中区分遗传性血管性水肿的临床和实验室特征
Allergol Int. 2014 Dec;63(4):595-602. doi: 10.2332/allergolint.14-OA-0700.
6
Identification of novel biomarkers to distinguish bradykinin-mediated angioedema from mast cell-/histamine-mediated angioedema.鉴定新型生物标志物以区分缓激肽介导的血管性水肿与肥大细胞/组胺介导的血管性水肿。
Allergy. 2022 Mar;77(3):946-955. doi: 10.1111/all.15013. Epub 2021 Jul 28.
7
Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema.复发性缓激肽介导与肥大细胞介导的血管性水肿患者的疾病活动度和生活质量评估
World Allergy Organ J. 2021 Jun 16;14(7):100554. doi: 10.1016/j.waojou.2021.100554. eCollection 2021 Jul.
8
Development of the Angioedema Control Test-A patient-reported outcome measure that assesses disease control in patients with recurrent angioedema.血管性水肿控制测试的开发——一种患者报告的结局指标,用于评估复发性血管性水肿患者的疾病控制情况。
Allergy. 2020 May;75(5):1165-1177. doi: 10.1111/all.14144. Epub 2020 Mar 6.
9
Predictive model to differentiate chronic histaminergic angioedema and chronic spontaneous urticaria with angioedema.用于鉴别慢性组胺能性血管性水肿和伴有血管性水肿的慢性自发性荨麻疹的预测模型。
J Allergy Clin Immunol Glob. 2024 May 9;3(3):100278. doi: 10.1016/j.jacig.2024.100278. eCollection 2024 Aug.
10
[Classification and pathophysiology of angioedema].[血管性水肿的分类与病理生理学]
Hautarzt. 2019 Feb;70(2):84-91. doi: 10.1007/s00105-018-4318-z.

本文引用的文献

1
The Role of Bradykinin Receptors in Hereditary Angioedema Due to C1-Inhibitor Deficiency.缓激肽受体在 C1 酯酶抑制剂缺乏所致遗传性血管性水肿中的作用。
Int J Mol Sci. 2022 Sep 7;23(18):10332. doi: 10.3390/ijms231810332.
2
The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update.《遗传性血管性水肿管理的国际 WAO/EAACI 指南-2021 年修订版》。
Allergy. 2022 Jul;77(7):1961-1990. doi: 10.1111/all.15214. Epub 2022 Feb 3.
3
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria.
国际 EAACI/GA²LEN/EuroGuiDerm/APAAACI 荨麻疹定义、分类、诊断和管理指南。
Allergy. 2022 Mar;77(3):734-766. doi: 10.1111/all.15090. Epub 2021 Oct 20.
4
Clinical and genetic features of hereditary angioedema with and without C1-inhibitor (C1-INH) deficiency in Japan.日本伴有和不伴有C1抑制剂(C1-INH)缺乏的遗传性血管性水肿的临床和遗传特征。
Allergy. 2021 Nov;76(11):3529-3534. doi: 10.1111/all.15034. Epub 2021 Aug 12.
5
Identification of novel biomarkers to distinguish bradykinin-mediated angioedema from mast cell-/histamine-mediated angioedema.鉴定新型生物标志物以区分缓激肽介导的血管性水肿与肥大细胞/组胺介导的血管性水肿。
Allergy. 2022 Mar;77(3):946-955. doi: 10.1111/all.15013. Epub 2021 Jul 28.
6
Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema.复发性缓激肽介导与肥大细胞介导的血管性水肿患者的疾病活动度和生活质量评估
World Allergy Organ J. 2021 Jun 16;14(7):100554. doi: 10.1016/j.waojou.2021.100554. eCollection 2021 Jul.
7
Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report.遗传性血管性水肿患者疾病负担与生活质量的评估及管理:一份共识报告
Allergy Asthma Clin Immunol. 2021 Apr 19;17(1):40. doi: 10.1186/s13223-021-00537-2.
8
Molecular Dambusters: What Is Behind Hyperpermeability in Bradykinin-Mediated Angioedema?分子“达姆破坏者”:缓激肽介导的血管性水肿中高通透性背后的原因是什么?
Clin Rev Allergy Immunol. 2021 Jun;60(3):318-347. doi: 10.1007/s12016-021-08851-8. Epub 2021 Mar 16.
9
Differences and Similarities in the Mechanisms and Clinical Expression of Bradykinin-Mediated vs. Mast Cell-Mediated Angioedema.缓激肽介导的血管性水肿与肥大细胞介导的血管性水肿在机制和临床表型方面的差异与相似之处。
Clin Rev Allergy Immunol. 2021 Aug;61(1):40-49. doi: 10.1007/s12016-021-08841-w. Epub 2021 Feb 3.
10
The Panorama of Primary Angioedema in the Brazilian Population.原发性血管性水肿在巴西人群中的全景。
J Allergy Clin Immunol Pract. 2021 Jun;9(6):2293-2304.e5. doi: 10.1016/j.jaip.2020.11.039. Epub 2020 Dec 2.